On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome Analysis.
Aldo BrassettiGiovanni E CacciamaniAndrea MariJuan D GaristoRiccardo BertoloChandru P SundaramIthaar DerweeshAhmet BindayiProkar DasguptaJames PorterAlexander MottrieLuigi SchipsKoon Ho RahDavid Y T ChenChao ZhangKenneth JacobsohnUmberto AnceschiAlfredo M BoveManuela CostantiniMariaconsiglia FerrieroRiccardo MastroianniLeonardo MisuracaGabriele TudertiAlexander KutikovWesley M WhiteStephen T RyanFrancesco PorpigliaJihad KaoukAndrea MinerviniInderbir GillRiccardo AutorinoGiuseppe SimonePublished in: Cancers (2022)
We compared perioperative outcomes after on-clamp versus off-clamp robot-assisted partial nephrectomy (RAPN) for >7 cm renal masses. A multicenter dataset was queried for patients who had undergone RAPN for a cT2cN0cM0 kidney tumor from July 2007 to February 2022. The Trifecta achievement (negative surgical margins, no severe complications, and ≤ 30% postoperative estimated glomerular filtration rate (eGFR) reduction) was considered a surrogate of surgical quality. Overall, 316 cases were included in the analysis, and 58% achieved the Trifecta. A propensity-score-matched analysis generated two cohorts of 89 patients homogeneous for age, ASA score, preoperative eGFR, and RENAL score (all p > 0.21). Compared to the on-clamp approach, OT was significantly shorter in the off-clamp group (80 vs. 190 min; p < 0.001), the incidence of sRFD was lower (22% vs. 40%; p = 0.01), and the Trifecta rate higher (66% vs. 46%; p = 0.01). In a crude analysis, >20 min of hilar clamping was associated with a significantly higher risk of sRFD (OR: 2.30; 95%CI: 1.13-4.64; p = 0.02) and with reduced probabilities of achieving the Trifecta (OR: 0.46; 95%CI: 0.27-0.79; p = 0.004). Purely off-clamp RAPN seems to be a safe and viable option to treat cT2 renal masses and may outperform the on-clamp approach regarding perioperative surgical outcomes.
Keyphrases
- robot assisted
- patients undergoing
- computed tomography
- small cell lung cancer
- contrast enhanced
- end stage renal disease
- minimally invasive
- magnetic resonance
- chronic kidney disease
- magnetic resonance imaging
- clinical trial
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- positron emission tomography
- dual energy
- early onset
- data analysis